Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
57.2M
-
Number of holders
-
94
-
Total 13F shares, excl. options
-
33.5M
-
Shares change
-
+1.42M
-
Total reported value, excl. options
-
$206M
-
Value change
-
+$9.37M
-
Put/Call ratio
-
0.57
-
Number of buys
-
46
-
Number of sells
-
-39
-
Price
-
$6.17
Significant Holders of Design Therapeutics, Inc. - Common Stock (DSGN) as of Q4 2024
114 filings reported holding DSGN - Design Therapeutics, Inc. - Common Stock as of Q4 2024.
Design Therapeutics, Inc. - Common Stock (DSGN) has 94 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.5M shares
of 57.2M outstanding shares and own 58.54% of the company stock.
Largest 10 shareholders include SR One Capital Management, LP (6.53M shares), Logos Global Management LP (4.22M shares), BlackRock, Inc. (2.58M shares), Frazier Life Sciences Management, L.P. (1.95M shares), Point72 Asset Management, L.P. (1.86M shares), BAKER BROS. ADVISORS LP (1.74M shares), TANG CAPITAL MANAGEMENT LLC (1.48M shares), VANGUARD GROUP INC (1.43M shares), Almitas Capital LLC (1.32M shares), and CITADEL ADVISORS LLC (959K shares).
This table shows the top 94 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.